This website is intended for healthcare professionals only.
MANAGEMENT OF mPaCa PATIENTS IN ASIA: WHAT ARE THE SPECIFIC FEATURES COMPARED WITH THE REST OF THE WORLD?
Prof Changhoon Yoo Assistant Professor Department of Oncology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
This webinar highlights the specificities of metastatic pancreatic cancer (mPaCa) management in Asian patients. While the efficacy outcomes of both 1L and 2L treatments do not differ between both populations, Asian and Caucasian patients have distinct safety profiles. An interactive case study is presented to discuss mPaCa patient care based on Professor Yoo's clinical experience.
Key points covered
This webinar discusses the similarities and differences between Caucasian and Asian populations when it comes to mPaCa management.
mPaCa is highly frequent in Asia; in 2020, nearly half of new pancreatic cancer cases were reported in Asia.
While FOLFIRINOX and nab-Paclitaxel + gemcitabine are both well-established 1L treatments in mPaCa, the latter is becoming the preferred option in Korea due to its favorable toxicity profile.
Nal-IRI+5-FU/LV is recognized as a standard 2L option post-gemcitabine for both Europe and Asia; Asian patients however present with a higher incidence of neutropenia and lower incidence of diarrhea with this treatment.
Webinar Replay
Featured Speakers
Prof Changhoon Yoo
Prof Changhoon Yoo is a medical oncologist who specializes in the care of patients with gastrointestinal cancers, particularly pancreatic cancer, cholangiocarcinoma, and hepatocellular carcinoma. He has participated in multiple clinical trials and translational research for the development of novel agents for patients with these cancers, and has authored and coauthored more than 100 research articles. His research initiatives include the integration of novel targeted and immune-based therapy into the treatment of hepatobiliary-pancreas cancers.
